AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02544425
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
Trial: NCT02544425
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
Trial: NCT02544425
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It will be administered 40mg/day PO or IV D1-3
Trial: NCT02544425
Drug: L-asparaginase
RxNorm normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
Trial: NCT02544425
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6
Trial: NCT02544425
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2
Trial: NCT03540875
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage is modified automatically by the device or according to the new medical prescription.
Trial: NCT01221402
Drug: extended-release niacin (Niaspan)
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
Trial: NCT00240994
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
Trial: NCT00240994
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
Trial: NCT00240994
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per recommendation
Trial: NCT00240994
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
Trial: NCT00746824
Drug: TM30339 and/or placebo
DrugBank: TM30339 (DB05085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
Trial: NCT02095145
Drug: Pomegranate-Extract Pill
RxNorm normalized name: pomegranate extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03676296
Drug: Puerarin
RxNorm normalized name: PUERARIN
DrugBank: Puerarin (DB12290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
Trial: NCT03155178
Drug: ChloraPrep
RxNorm normalized name: ChloraPrep
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply topically to intact dry skin (abdominal site) for 30 seconds or moist skin (inguinal site) for 2 minutes.
Trial: NCT00032188
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00937040
Drug: OROS MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
Trial: NCT00937040
Drug: OROS MPH Tablets
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
Trial: NCT03596281
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg Q3W IV
Trial: NCT03596281
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 or 300 mg Q3W IV
Trial: NCT00000238
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04998279
Drug: Granulocyte Colony-Stimulating Factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte-colony stimulating factors (G-CSF) is synthesized in the reproductive tract naturally, it is a hematopoietic lineage-specific cytokine which is known for its specific effects on the activation of intracellular signaling pathways that are associated with the cell proliferation, differentiation, and stimulation of hematopoietic cells of the neutrophilic granulocyte lineage; which act on macrophages of decidual cells and finally affect implantation
Trial: NCT03898479
Drug: CTP-543
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Twice daily dosing
Trial: NCT00638443
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
Trial: NCT00638443
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
Trial: NCT02377479
Drug: Clomiphene
RxNorm normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken for controlled ovarian hyperstimulation.
Trial: NCT02377479
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken for controlled ovarian hyperstimulation
Trial: NCT00981045
Drug: Ferric Carboxymaltose (FCM)
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
Trial: NCT00981045
Drug: Iron Sucrose (Venofer)
RxNorm normalized name: iron sucrose Injection [Venofer]
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 doses of 200 mg for a total cumulative dose of 1000 mg
Trial: NCT01864915
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
Trial: NCT00892125
Drug: paliperidone ER; Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01896284
Drug: 0.5mg aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
Trial: NCT02223884
Drug: docetaxel 35mg/m2
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
Trial: NCT02223884
Drug: Carboplatin AUC3
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
Trial: NCT02630186
Drug: Rociletinib
RxNorm normalized name: rociletinib
DrugBank: Rociletinib (DB11907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
Trial: NCT00738881
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00738881
Drug: Pemetrexed Disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01205126
Drug: Hydromorphone HCl
RxNorm normalized name: hydromorphone HCl
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
Trial: NCT01205126
Drug: Oxycodone HCl CR
RxNorm normalized name: Oxycodone Hydrochloride 10 MG Oral Tablet, Extended Release [OXYCODONE HCL CR]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
Trial: NCT00486954
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 pills at 250 mg each once daily
Trial: NCT00486954
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion at 80 mg/m2 weekly
Trial: NCT00768755
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID po up to max 10mg BID po
Trial: NCT00768755
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Trial: NCT00768755
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
Trial: NCT03700333
Drug: Pemetrexed therapy
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(\>21 days).
Trial: NCT00387751
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01250535
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg, po, single dose on day 7
Trial: NCT02445404
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1\~5 every 3 weeks
Trial: NCT01756261
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients treated with EYLEA under practical manner for AMD.
Trial: NCT00004410
Drug: tauroursodeoxycholic acid
RxNorm normalized name: tauroursodeoxycholic acid
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02565719
Drug: Pegasys
RxNorm normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immunotherapy
Trial: NCT02565719
Drug: Viread
RxNorm normalized name: Viread
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBV RT polymerase inhibitor
Trial: NCT00800306
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
Trial: NCT00800306
Drug: dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
Trial: NCT02753309
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00855595
Drug: Azelaic acid (Finacea, BAY39-6251)
RxNorm normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received topical azelaic acid gel 15% twice daily for 12 weeks
Trial: NCT00855595
Drug: Metronidazole (Metrogel)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received topical metronidazole 1% gel once daily for 12 weeks
Trial: NCT00004408
Drug: poloxamer 188
RxNorm normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04037072
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of Mytomycin C (MMC)
Trial: NCT05526807
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00286923
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00122538
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00122538
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00122538
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02677038
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04305249
Drug: ATG-017
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
Trial: NCT04305249
Drug: ATG-017+Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
Trial: NCT01646021
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 560 mg once daily continuous (without interruption) by mouth for 21-day cycles
Trial: NCT01646021
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
Trial: NCT04525079
Drug: CT-P59
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P59 will be administered
Trial: NCT03114280
Drug: TPF2
RxNorm normalized name: Trifluoperazine
DrugBank: Trifluoperazine (DB00831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
Trial: NCT00615186
Drug: Neuradiab + Radiotherapy + Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
Trial: NCT00615186
Drug: Radiation Therapy + Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prior Surgery: Gross total resection (\< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment.
Trial: NCT01824615
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5mg everyday from D1-D28
Trial: NCT01626222
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
Trial: NCT00455559
Drug: Perifosine
RxNorm normalized name: Perifosine
DrugBank: Perifosine (DB06641)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00455559
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00540956
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01157624
Drug: oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects who are found to desaturate during treatment with air will be supplement with oxygen
Trial: NCT00851513
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthetics
Trial: NCT01626222
Drug: Everolimus (RAD001)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
Trial: NCT00723099
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00723099
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV